Clinical trials: Lymphoma, Hodgkins
Leukemia, Non Hodgkin Lymphoma
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
- Trial name
- NCT05425992
- Testing
- Interview
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Solid Tumor, Non-Hodgkin Lymphoma
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma.
- Trial name
- NCT03802955
- Testing
- ADG106
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Adagene (Suzhou) Limited
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Double Cord Versus Haploidentical (BMT CTN 1101)
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular Lymphoma
- Trial name
- NCT01597778
- Testing
- Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
- Where
- 39 sites in United States
- Volunteers
- 368 people
- Sponsor
- Medical College of Wisconsin
Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
- Conditions
- Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
- Trial name
- NCT04788043
- Testing
- Magrolimab, Pembrolizumab, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Ranjana Advani
AIDS Related Lymphoma
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
Most treatment procedures in AIDS-related lymphomas disclose a relatively poor outcome for patients with low response rates, high number of relapses and AIDS events.
- Trial name
- NCT00126243
- Testing
- rituximab, CHOP
- Where
- France
- Volunteers
- 60 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT)
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.
- Trial name
- NCT00186589
- Testing
- 90Y Ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Leukemia, Lymphoma
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating patients who have non-Hodgkin's lymphoma or…
- Trial name
- NCT00024115
- Testing
- BL22 immunotoxin, antibody therapy, biological response modifier therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Solid Cancers
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid…
- Trial name
- NCT00854126
- Testing
- GDC-0980
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Genentech, Inc.
B-Cell Non-Hodgkin Lymphoma
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy in adult patients with relapsed or refractory (r/r) CD19-positive B-cell Non-Hodgkin Lymphoma (B-NHL) or B-cell Leukemia.
- Trial name
- NCT07584850
- Testing
- GI001 Injection
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT05490043
- Testing
- ATG-101
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Antengene (Hangzhou) Biologics Co., Ltd.
Non-Hodgkin's Lymphoma
Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) incidence rates have risen three percent per year in the U.S. for four decades. Mortality from NHL has risen 1.6 percent, compared with 0.2 percent for all cancers combined.
- Trial name
- NCT00341952
- Where
- 4 sites in United States
- Volunteers
- 2,378 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002714
- Testing
- bleomycin sulfate, Stanford V regimen, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Stanford University
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma
- Trial name
- NCT04447716
- Testing
- Venetoclax, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Lymphomas Non-Hodgkin's B-Cell
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years of age with relapsed or refractory CD19+…
- Trial name
- NCT03379493
- Testing
- ET190L1 ARTEMIS™ T cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Eureka Therapeutics Inc.
Non-Hodgkin's Lymphoma
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally.
- Trial name
- NCT02697552
- Testing
- HBI-8000
- Where
- 8 sites in Japan
- Volunteers
- 13 people
- Sponsor
- HUYABIO International, LLC.
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Diffuse Large-Cell Lymphoma
Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV
Early identification of refractory lymphoma patients provides a basis for stratification between responders to standard approaches and non-responders who may benefit from an early change to an alternative treatment…
- Trial name
- NCT00286832
- Testing
- PET scan
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital at Herlev
Lymphoma
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT01190449
- Testing
- ofatumumab
- Where
- 48 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.